The firm will use to funds to validate its CD123-targeted CAR T-cell therapies in acute myeloid leukemia in clinical studies.

Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.

Broad Institute and Northwestern University researchers are encouraging others to examine non-coding genes, when ...

About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.

NEW YORK – Cancer Research UK and Australian charity the Minderoo Foundation said on Wednesday they are collectively committing approximately £3.4 million (about $4.4 million) to fund an adaptive ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

The firm will put the funds toward advancing its autologous CAR T-cell therapy MB-105 into Phase II clinical trials in CD5-positive lymphoma.

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...

Swedish regulators cleared a clinical trial application, allowing Karolinska University Hospital investigators to begin studying 177Lu-AKIR001.

The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.

The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.

The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.